Based on Type of Packaging, Single-Use Vials Segment to Account for Largest Share of global Lyophilized Injectable Market during 2022-2028. Rising use of single-use vials owing to various advantages such as ease in self administration and reduction in medical waste along with the increase in home healthcare and self-administration of drugs is expected to generate demand for single use vials packaging and contribute the market growth over the forecast period.

According to our latest study on "Lyophilized Injectable Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Type of Packaging, Type of Delivery, Indication, and End User," the market is projected to reach US$ 4,001.27 million by 2028 from US$ 2,719.42 million in 2021; it is expected to grow at a CAGR of 5.8% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the global lyophilized injectable market.

The outbreak of COVID-19 pandemic had a positive impact on lyophilized injectable market growth. The rise in the COVID-19 cases along with the increase in prevalence of chronic disorders, including cancer, metabolic conditions, and autoimmune disorders led to huge investments for the development of lyophilized injectable which drives the growth of market during the pandemic. Moreover, the launch of COVID-19 vaccines, such as remdesivir, and cosentyx, approved by the Food and Drug Administration (FDA) for emergency use has also generated the demand for lyophilized injectable. Moreover, surge in infectious diseases, increasing use of antibiotics for infectious diseases, rising inclination toward biologics, and surging contract research organizations will propel the growth of the lyophilized drugs market. Moreover, various advantages offered by lyophilized injectable include easy transportation, storage, reconstitution, reduction in cold chain, and reduced carbon footprint. Overall, the COVID-19 pandemic has positive impact on the lyophilized injectable market.

Based on type of packaging, the is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment is likely to account for the largest market share during 2022-2028. By type of delivery, the market is segmented into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held the largest market share in 2021 and is likely to continue its dominance during the forecast period. Based on indication, the global lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment is likely to account for the largest market share during 2022-2028. By end user, the market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held the largest market share in 2021 and is likely to continue its dominance during the forecast period.

The pharmaceutical industry is shifting from large-scale production to niche and targeted therapies (personalized medicine). The rising demand for flexible operational capabilities, high production scales, and multiple-product operations is offering significant advantages to contract manufacturing organizations (CMOs). Many companies are opting CMOs services to speed up the development process and lower production costs. For instance, in 2019, Dyadic International, Inc. agreed with Luina Bio Pty Ltd for the development and commercialization of its specific targeted antigen and biological products. Thus, the importance of lyophilization in the successful delivery of biologics boosts the use of lyophilized injectable.

Baxter; Nipro; Curia Global, Inc.; Recipharm AB; Vetter Pharma; Jubilant HollisterStier LLC (Jubilant Pharma Limited); Aristopharma Ltd.; CordenPharma International; Credence MedSystems, Inc.; and S. G. Biopharm Pvt. Ltd. are among the leading companies operating in the global lyophilized injectable market.

Based on geography, the global lyophilized injectable market is primarily segmented into North America, Europe, Asia Pacific, South and Central America, and Middle East and Africa (MEA). The market in North America is further segmented into the US, Canada, and Mexico. The European market is subsegmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market in Asia Pacific is subsegmented into China, India, Japan, South Korea, Australia, and the Rest of APAC. The market in South and Central America is subsegmented into Brazil, Argentina, and the Rest of South and Central America. The lyophilized injectable market in the MEA is further segmented into South Africa, Saudi Arabia, the UAE, and the Rest of MEA.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com